FDA Workshop Highlights Promise, Risks Of AI In Generic Drug Reviews
FDA and industry stakeholders are eyeing artificial intelligence as a way to make generic drug development and review more efficient, ...
Read the original at insidehealthpolicy.com ↗
- Topics
- Healthcare
- Mentions
- FDA
- Tracked via
- “AI Risks”